ROSEMARY OKOROAFOR: Open Payments
NPI 1760031165 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$525 in 5 payments from 4 companies in 2025. Trend: 2023 $201 · 2024 $114 · 2025 $525
Food & beverage: $525
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $140 |
| Otsuka America Pharmaceutical, Inc. | 2 | $135 |
| Neurocrine BioSciences, Inc. | 1 | $135 |
| Janssen Pharmaceuticals, Inc | 1 | $115 |
Products named: AUSTEDO XR, ABILIFY ASIMTUFII, INGREZZA, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
